Neurotech Investors Back Capital Raisings and Director Participation at General Meeting

Neurotech International ( (AU:NTI) ) has provided an update.

Neurotech International has reported the results of its 12 March general meeting in Melbourne, where all resolutions were decided by poll, including the ratification of previously issued placement shares and approvals for additional equity issuance. Shareholders also backed director participation in the capital placement and authorised the issue of further placement shares, reinforcing the company’s funding base to support ongoing clinical development of its paediatric neurological drug pipeline.

The strong support across all resolutions suggests investors remain aligned with Neurotech’s capital-raising strategy and governance approach, particularly around management’s financial commitment through placement participation. This outcome provides the company with greater flexibility to advance late-stage trials for NTI164 in Autism Spectrum Disorder and related paediatric neurological conditions, potentially strengthening its competitive position in the emerging cannabinoid-based therapeutics market.

The most recent analyst rating on (AU:NTI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.

More about Neurotech International

Neurotech International is a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, developing a broad-spectrum oral cannabinoid therapy known as NTI164. The company has reported statistically significant and clinically meaningful results across multiple Phase I/II and Phase II/III trials in Autism Spectrum Disorder, PANDAS/PANS and Rett Syndrome, and has ethics clearance for a Phase III ASD study.

Average Trading Volume: 1,485,907

Technical Sentiment Signal: Sell

Current Market Cap: A$14.26M

Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.